Table 3.

Comparison of key performance measures and clinical outcomes, Pre-ASCaM versus ASCaM period

	Pre-ASCaM (N=189)	ASCaM (N=317)	P value	Unadjusted OR (95 % CI) or β	P value	Adjusted OR (95 % CI) or β	P value
tPA within 4.5 hours, %	54.5% (189/347)	65.4% (317/485)	0.0015	1.235 (1.08 to 1.41)	0.0015	1.724 (1.21 to 2.45)*	0.003*
ODT (Mean±SD)	135.7±58.4	114.1±55.7	<0.001	−22.02922	<0.0001	−20.59164	0.0002
DNT (Mean±SD)	57.1±30.6	56.1±25.3	0.6838	−0.91595	0.7188	−0.24447	0.9260
ONT (Mean±SD)	195.6±59.3	169.2±58.1	<0.001	−26.74615	<0.0001	−24.89451	<0.0001
Favourable outcome (mRS ≤2), n (%)	151 (79.9%)	270 (85.2%)	0.1244	0.677 (0.422 to 1.087)	0.1064	0.761 (0.444 to 1.306)	0.3222
sICH, n (%)	6 (3.2%)	10 (3.2%)	0.9901	1.003 (0.359 to 2.806)	0.9950
In-hospital mortality	6 (3.2%)	8 (2.5%)	0.6659	1.262 (0.431 to 3.696)	0.6708

For multivariate analysis, data were adjusted for patient-level factors, including age, sex, medical history (including atrial fibrillation or atrial flutter, prosthetic heart valve, previous stroke or transient ischemic attack, coronary artery disease or prior myocardial infarction, carotid stenosis, peripheral vascular disease, hypertension, dyslipidaemia, seizure and current smoking), stroke severity (NIHSS score).

*Data were adjusted for the contribution of thrombolytic cases from every individual hospitals.

ASCaM, Acute Stroke Care Map; DNT, door-to-needle time; mRS, modified Rankin Scale; NIHSS, National Institute of Health Stroke Scale; ODT, onset-to-door time; ONT, onset-to-needle time; sICH, symptomatic intracerebral haemorrhage.